Otmane brings over 25 years of leadership in shaping and driving successful global technical development organizations within the biopharmaceutical industry. He joined Anjarium from Sensorion, where he served as Chief Technology Officer (CTO) in the clinical-stage biotech sector. Prior to Sensorion, Otmane spent six years at Novartis, holding pivotal roles, including Global Head of Cell & Gene Therapy Technical Development and Global Head of Early Phase Development. During his tenure, he established a dedicated unit overseeing all cell and gene therapy modalities and contributed significantly to numerous Investigational new drug programs. His extensive experience also includes roles at Sanofi and EMD Serono.
Otmane has been instrumental in leading innovation across organization setups, technology and bioprocess development, process scale-up, and tech transfer. He offers robust support in bio-manufacturing, Manufacturing Sciences & Technology (MS&T), and Analytical Sciences & Technology (AS&T). Otmane possesses a profound understanding of regulatory requirements for filing biologics, vaccines, and cell and gene therapy modalities (IND/IMPD/BLA/MAA), demonstrated by an extensive track record of successful submissions.
Otmane earned a Doctor of Science in Applied Biological and Fundamental Sciences from the Université Louis Pasteur in Strasbourg (ULP), alongside a Master’s Degree in Organic Chemistry and Molecular & Supramolecular from ULP.
